Want to see AU:ANR full AI Analyst Report?
ANR Stock Chart & Stats
AU$0.01
<AU$0.01(3.85%)
At close: 4:00 PM EST
AU$0.01
<AU$0.01(3.85%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume35.84K
Average Volume (3M)59.97K
Market Cap
AU$2.85M
Enterprise ValueAU$2.69
Total Cash (Recent Filing)AU$470.92K
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Feb 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding316,310,400
10 Day Avg. Volume50,098
30 Day Avg. Volume59,972
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.91
Price to Sales (P/S)0.00
P/FCF Ratio-8.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetZero debt reduces mandatory financing costs and near-term leverage risk, while positive equity provides a stronger capital base. This gives Anatara greater flexibility to fund development or pursue partnerships, although continued losses could reduce that cushion.
Narrower Net LossesThe reduction in net losses indicates some progress in controlling the earnings deficit, even though profitability has not been achieved. If sustained, this could improve capital efficiency and reduce the scale of future funding requirements.
Focused Gastrointestinal Product StrategyA focused gastrointestinal-health strategy can concentrate limited research resources around a defined therapeutic and consumer need. Oral delivery may support product usability, while clinical evaluation and partnership preparation provide potential routes toward future commercialization.
Bears Say
Revenue DeteriorationThe loss of reported revenue leaves no established top-line base to support ongoing operations or validate commercial traction. Rebuilding consistent sales will be essential before Anatara can demonstrate recurring demand, operating leverage, or meaningful scale.
Persistent UnprofitabilityPersistent operating and net losses, combined with negative gross profit, show that current economics do not cover the cost of generating revenue. Without durable margin improvement, growth or commercialization could require substantial additional capital.
Dependence On External FundingNegative operating and free cash flow indicate that the business cannot currently self-fund its activities. Continued dependence on external capital raises execution and dilution risk, particularly if commercialization takes longer or financing conditions become less supportive.
Anatara Lifesciences Ltd News
ANR FAQ
What was Anatara Lifesciences Ltd’s price range in the past 12 months?
Anatara Lifesciences Ltd lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Anatara Lifesciences Ltd’s market cap?
Anatara Lifesciences Ltd’s market cap is AU$2.85M.
When is Anatara Lifesciences Ltd’s upcoming earnings report date?
Anatara Lifesciences Ltd’s upcoming earnings report date is Feb 24, 2027 which is in 155 days.
How were Anatara Lifesciences Ltd’s earnings last quarter?
Anatara Lifesciences Ltd released its earnings results on Aug 26, 2026. The company reported -AU$0.001 earnings per share for the quarter.
Is Anatara Lifesciences Ltd overvalued?
According to Wall Street analysts Anatara Lifesciences Ltd’s price is currently Overvalued.
Does Anatara Lifesciences Ltd pay dividends?
Anatara Lifesciences Ltd does not currently pay dividends.
What is Anatara Lifesciences Ltd’s EPS estimate?
Anatara Lifesciences Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anatara Lifesciences Ltd have?
Anatara Lifesciences Ltd has 316,310,400 shares outstanding.
What happened to Anatara Lifesciences Ltd’s price movement after its last earnings report?
Anatara Lifesciences Ltd reported an EPS of -AU$0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Anatara Lifesciences Ltd?
Currently, no hedge funds are holding shares in AU:ANR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anatara Lifesciences Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastrointestinal ReProgramming (GRP), a proprietary blend combining bromelain with other evidence-based ingredients, specifically formulated to target the underlying issues of human gastrointestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. The firm also offers 3FDC, designed to address anxiety, stress, or depression. In the animal health sector, Anatara provides Detach for treating diarrhea in piglets, BONIFF as an enhanced dry feed formulation for weaned piglets, and ANR-pf, a unique additive for poultry drinking water. This company was founded in 2010 and is headquartered in Carlton, Australia.
Technical Analysis
Immuron Limited
―
Botanix Pharmaceuticals Limited
―
EZZ Life Science Holdings Ltd.
―
Biome Australia Ltd
―
Recce Pharmaceuticals Ltd.
―